Previous 10 | Next 10 |
home / stock / braxf / braxf news
Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario Canada NewsWire Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of ter...
Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022 Canada NewsWire TORONTO , May 19, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical r...
Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry Canada NewsWire TORONTO , May 18, 2022 /CNW/ - Braxia Scientific Corp. ...
Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6 Canada NewsWire TORONTO , April 1, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scient...
Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada Canada NewsWire Achieved milestone with the start of landmark psilocybin clinical trial in Q3 2021...
Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development Canada NewsWire TORONTO , Jan. 31, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "...
Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin Canada NewsWire Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Brax...
Braxia Scientific (OTCPK:BRAXF): FQ2 Net loss for the quarter decreased 16% Y/Y to $1.71M. Revenue of C$0.39M (+56.0% Y/Y) Press Release The Company's cash and cash equivalents as of September 30, 2021, was C$9.61M compared with C$10.26M at June 30, 2021. For further details see: ...
Braxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMD Canada NewsWire TORONTO , Nov. 9, 2021 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical re...
Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami Canada NewsWire TORONTO , Nov. 8, 2021 /CNW Telbec/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company wi...
News, Short Squeeze, Breakout and More Instantly...
Braxia Scientific Corp Company Name:
BRAXF Stock Symbol:
OTCMKTS Market:
Braxia Scientific Corp Website:
Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), today announced that it has made an application to the Ontario Securities Commission to approve a management cease trade order ("MCTO") ...
Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders...
Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders,...